The memory ameliorating effects of novel N-benzyl pyridine-2-one derivatives on scopolamine-induced cognitive deficits in mice.
N-Benzyl pyridine-2-one
Acetylcholinesterase
Alzheimer’s disease
Donepezil
Scopolamine
Journal
Laboratory animal research
ISSN: 1738-6055
Titre abrégé: Lab Anim Res
Pays: England
ID NLM: 101560684
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
01
09
2023
accepted:
13
12
2023
revised:
07
12
2023
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
epublish
Résumé
Alzheimer's disease (AD), the most common form of progressive dementia in the elderly, is a chronic neurological disorder that decreases cognitive ability. Although the underlying cause of AD is yet unknown, oxidative stress and brain acetylcholine shortage are the key pathogenic causes. The current study shows that these derivatives have the potential to improve memory in mice by inhibiting scopolamine-induced acetylcholinesterase activity, oxidative and nitrosative stress, and improving locomotor activity and muscle grip strength in the rota rod test. When compared to the illness control, the memory-enhancing potential of novel N-benzyl pyridine-2-one derivatives was highly significant (P < 0.0001). The observed memory ameliorating effect of novel N-benzyl pyridine-2-one makes them as a a good choice for treatment of individuals with cognitive impairment.
Sections du résumé
BACKGROUND
BACKGROUND
Alzheimer's disease (AD), the most common form of progressive dementia in the elderly, is a chronic neurological disorder that decreases cognitive ability. Although the underlying cause of AD is yet unknown, oxidative stress and brain acetylcholine shortage are the key pathogenic causes.
RESULTS
RESULTS
The current study shows that these derivatives have the potential to improve memory in mice by inhibiting scopolamine-induced acetylcholinesterase activity, oxidative and nitrosative stress, and improving locomotor activity and muscle grip strength in the rota rod test. When compared to the illness control, the memory-enhancing potential of novel N-benzyl pyridine-2-one derivatives was highly significant (P < 0.0001).
CONCLUSIONS
CONCLUSIONS
The observed memory ameliorating effect of novel N-benzyl pyridine-2-one makes them as a a good choice for treatment of individuals with cognitive impairment.
Identifiants
pubmed: 38468315
doi: 10.1186/s42826-023-00187-y
pii: 10.1186/s42826-023-00187-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© 2024. The Author(s).
Références
Zhang J, Shi L, Shen Y. The retina: a window in which to view the pathogenesis of Alzheimer’s disease. Ageing Res Rev. 2022;77: 101590.
doi: 10.1016/j.arr.2022.101590
pubmed: 35192959
Lynch C. World Alzheimer Report 2019: attitudes to demnetia, a global survey. Alzheimer’s Dement. 2020;16: e038255.
doi: 10.1002/alz.038255
Pant S, Gupta M, Anthwal T, Chauhan M, Nain S. Neuroprotective effects of novel pyrrolidine-2-one derivatives on scopolamine-induced cognitive impairment in mice: Behavioral and biochemical analysis. Pharmacol Biochem Behav. 2023;229: 173602.
doi: 10.1016/j.pbb.2023.173602
pubmed: 37453560
Bhatia V, Sharma S. Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer’s disease. J Neurol Sci. 2021;421: 117253.
doi: 10.1016/j.jns.2020.117253
pubmed: 33476985
Talesa VN. Acetylcholinesterase in Alzheimer’s disease. Mech Ageing Dev. 2001;122:1961–9.
doi: 10.1016/S0047-6374(01)00309-8
pubmed: 11589914
Arce MP, Rodríguez-Franco MI, González-Muñoz GC, Pérez C, López B, Villarroya M, et al. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer’s disease. J Med Chem. 2009;52:7249–57.
doi: 10.1021/jm900628z
pubmed: 19856923
Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC. A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci Ther. 2018;24(10):876–88.
doi: 10.1111/cns.13035
pubmed: 30058285
pmcid: 6489741
Marucci G, Buccioni M, Dal Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology. 2021;190: 108352.
doi: 10.1016/j.neuropharm.2020.108352
pubmed: 33035532
Ayaz M, Ullah F, Sadiq A, Kim MO, Ali T. Editorial: Natural products-based drugs: potential therapeutics against Alzheimer’s disease and other neurological disorders. Front Pharmacol. 2019;10:1417.
doi: 10.3389/fphar.2019.01417
pubmed: 31849668
pmcid: 6889855
Ahmed S, Khan ST, Zargaham MK, Khan AU, Khan S, Hussain A, et al. Potential therapeutic natural products against Alzheimer’s disease with reference of Acetylcholinesterase. Biomed Pharmacother. 2021;139: 111609.
doi: 10.1016/j.biopha.2021.111609
pubmed: 33915501
Gupta M, Kumar A, Prasun C, Nair MS, Kini SG, Yadav D, et al. Design, synthesis, extra-precision docking, and molecular dynamics simulation studies of pyrrolidin-2-one derivatives as potential acetylcholinesterase inhibitors. J Biomol Struct Dyn. 2023;41(13):6282–94.
doi: 10.1080/07391102.2022.2106515
pubmed: 35921217
Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington’s disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol. 2009;615(1–3):91–101.
doi: 10.1016/j.ejphar.2009.04.058
pubmed: 19445928
Goverdhan P, Sravanthi A, Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis. 2012;2012: 974013.
pubmed: 22536538
pmcid: 3320018
Saxena G, Singh SP, Agrawal R, Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol. 2008;581(3):283–9.
doi: 10.1016/j.ejphar.2007.12.009
pubmed: 18234183
Giovannini MG, Spignoli G, Carlà V, Pepeu G. A decrease in brain catecholamines prevents oxiracetam antagonism of the effects of scopolamine on memory and brain acetylcholine. Pharmacol Res. 1991;24(4):395–405.
doi: 10.1016/1043-6618(91)90044-X
pubmed: 1805193
Gupta M, Ojha M, Yadav D, Pant S, Yadav R. Novel benzylated (pyrrolidin-2-one)/(imidazolidin-2-one) derivatives as potential anti-Alzheimer’s agents: synthesis and pharmacological investigations. ACS Chem Neurosci. 2020;11(18):2849–60.
doi: 10.1021/acschemneuro.0c00403
pubmed: 32816447
Lee JS, Kim HG, Han JM, Kim DW, Yi MH, Son SW, et al. Ethanol extract of Astragali Radix and Salviae Miltiorrhizae Radix, Myelophil, exerts anti-amnesic effect in a mouse model of scopolamine-induced memory deficits. J Ethnopharmacol. 2014;153(3):782–92.
doi: 10.1016/j.jep.2014.03.048
pubmed: 24690775
Shi J, Liu Q, Wang Y, Luo G. Coadministration of huperzine A and ligustrazine phosphate effectively reverses scopolamine-induced amnesia in rats. Pharmacol Biochem Behav. 2010;96(4):449–53.
doi: 10.1016/j.pbb.2010.07.004
pubmed: 20624417
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.
doi: 10.1016/j.biocel.2006.07.001
pubmed: 16978905
Fukui K, Omoi NO, Hayasaka T, Shinnkai T, Suzuki S, Abe K, et al. Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Ann N Y Acad Sci. 2002;959:275–84.
doi: 10.1111/j.1749-6632.2002.tb02099.x
pubmed: 11976202
Khalifa AE. Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004;23(9):439–45.
doi: 10.1191/0960327104ht470oa
pubmed: 15497819
Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, et al. Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett. 2005;374(3):222–6.
doi: 10.1016/j.neulet.2004.10.063
pubmed: 15663967
Jeong EJ, Ma CJ, Lee KY, Kim SH, Sung SH, Kim YC. KD-501, a standardized extract of Scrophularia buergeriana has both cognitive-enhancing and antioxidant activities in mice given scopolamine. J Ethnopharmacol. 2009;121(1):98–105.
doi: 10.1016/j.jep.2008.10.006
pubmed: 18996178
Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47–60.
doi: 10.1016/0165-0270(84)90007-4
pubmed: 6471907
Vogel HG, Schlkens BA, Sandow J. Drug effects on learning and memory. Drug Discov Eval Pharmacol Assays. 2002;2:595–643.
doi: 10.1007/3-540-29837-1_7
Kulkarni SK. Handbook of experimental pharmacology. Vallabh Prakashan; 1987.
Abhinav K, Jogender M, Madhusudana K, Naidu VGM, Gupta YK. Anti-amnesic activity of Vitex negundo in scopolamine induced amnesia in rats. Pharmacol Pharm. 2010;1:1–8.
doi: 10.4236/pp.2010.11001
Kumar A, Dogra S, Prakash A. Neuroprotective effects of Centella asiatica against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis. 2009;2009: 972178.
pubmed: 20798885
pmcid: 2925281
Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966;99(3):667–76.
doi: 10.1042/bj0990667
pubmed: 5964963
pmcid: 1265056
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7.
doi: 10.1016/0003-9861(59)90090-6
pubmed: 13650640
Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys. 1978;186(1):189–95.
doi: 10.1016/0003-9861(78)90479-4
pubmed: 24422
Luck H. Catalase. In: Bergmeyer HU, editor. Method of enzymatic analysis. Academic Press: New York and London; 1965. p. 885–94.
doi: 10.1016/B978-0-12-395630-9.50158-4
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannebaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982;126(1):131–8.
doi: 10.1016/0003-2697(82)90118-X
pubmed: 7181105